{
    "organizations": [],
    "uuid": "2bf0b847299efb5ef986894734a6092ccbe7a1f0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-madrigals-mgl-3196-achieves-primar/brief-madrigals-mgl-3196-achieves-primary-endpoint-in-patients-with-heterozygous-familial-hypercholesterolemia-idUSFWN1PY10K",
    "ord_in_thread": 0,
    "title": "Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Heterozygous Familial Hypercholesterolemia",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 8 (Reuters) - Madrigal Pharmaceuticals Inc:\n* MADRIGALâ€˜S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)\n* MADRIGAL PHARMACEUTICALS- STATISTICALLY SIGNIFICANT IMPROVEMENT ACHIEVED IN REDUCTION OF LDL CHOLESTEROL (LDL-C) WITH MGL-3196 COMPARED TO PLACEBO\n* MADRIGAL PHARMACEUTICALS INC - MGL-3196 WAS WELL TOLERATED IN THE TRIAL AS COMPARED TO PLACEBO\n* MADRIGAL PHARMACEUTICALS- LDL-C LOWERING WAS 28.5% IN MGL-3196 TREATED VERSUS PLACEBO IN PRESPECIFIED GROUP OF PATIENTS WHO DIDNT TOLERATE HIGH INTENSITY STATIN DOSES\n* MADRIGAL PHARMACEUTICALS- THERE WERE 2 SERIOUS ADVERSE EVENTS IN STUDY, BOTH UNRELATED TO TREATMENT, ONE IN A PLACEBO AND ONE IN A DRUG-TREATED PATIENT ",
    "published": "2018-02-08T20:01:00.000+02:00",
    "crawled": "2018-02-08T14:16:19.031+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "madrigal",
        "pharmaceutical",
        "inc",
        "madrigal",
        "achieves",
        "primary",
        "endpoint",
        "patient",
        "heterozygous",
        "familial",
        "hypercholesterolemia",
        "hefh",
        "madrigal",
        "statistically",
        "significant",
        "improvement",
        "achieved",
        "reduction",
        "ldl",
        "cholesterol",
        "compared",
        "placebo",
        "madrigal",
        "pharmaceutical",
        "inc",
        "well",
        "tolerated",
        "trial",
        "compared",
        "placebo",
        "madrigal",
        "lowering",
        "treated",
        "versus",
        "placebo",
        "prespecified",
        "group",
        "patient",
        "didnt",
        "tolerate",
        "high",
        "intensity",
        "statin",
        "dos",
        "madrigal",
        "serious",
        "adverse",
        "event",
        "study",
        "unrelated",
        "treatment",
        "one",
        "placebo",
        "one",
        "patient"
    ]
}